Abdul Mannan Inside the Diagnostic Maze of Atypical CML
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
”It’s rare. It’s aggressive. It mimics other blood cancers.
No Philadelphia chromosome. No targeted therapy. Just tough decisions.
Diagnosis needs sharp eyes. Dysplastic cells. High white counts. Molecular clues.
SETBP1 and ASXL1 mutations tell the story.
CSF3R points elsewhere.
Median survival? 14-30 months without transplant.
But here’s hope: Early recognition matters. Molecular testing guides us. Transplant can cure selected patients.
Every rare diagnosis teaches us something profound about blood biology.
As haematologists, we don’t just treat diseases. We solve puzzles that save lives.
What rare condition taught you the most?”
Keep up with Hemostasis Today.
-
Oct 5, 2026, 10:24Vishnu Priya Pulipati: The Endocrinologist’s Role in Lp(a) and Cardiovascular Risk Reduction
-
Oct 5, 2026, 09:59William McKeown – A Busy Week with the European Haemophilia Consortium
-
Oct 5, 2026, 09:46Megan Buchholz – Celebrating Apheresis Awareness Day 2026 at St. Michael’s Hospital
-
Oct 5, 2026, 09:34ITP Myth vs. Fact – A Common Misconception – ITP Support Association
-
Oct 5, 2026, 09:20Jan Sloves: Medial Thigh Venous Perforators – Why Diameter Isn’t the Whole Story
-
Oct 5, 2026, 09:16Emmanuele Kouvousis: ASH Sets New Standards for Diagnosing Iron Deficiency
-
Oct 5, 2026, 09:12Arun V J: Fresh Whole Blood vs Evidence-Based Transfusion
-
Oct 5, 2026, 09:06Edward Lee Carter: NOTION-4 – HALT and Clinical Outcomes
-
Oct 4, 2026, 15:06Vasiliki Gkalea: Journal of Clinical Medicine Launches Special Issue on Hematologic Thrombosis and Bleeding